Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 4, 2021

View Archived Issues

Bicycle Therapeutics targets nectin-4 and CD137 with BT-7480

WDR5 degrader MS-67 shows promise against AML in murine model

Colchicine shows promise in a rimmed vacuolar myopathy model

ADA2-mediated signaling promotes liver fibrosis in NAFLD

New and known compounds targeting PTPRD may treat AD, addiction and restless legs syndrome

Novel theranostic agent shows potential for immune-PET imaging and TRT in models of gliomas

Keaise Medicine patents TRXR inhibitors

Disarm Therapeutics discloses SARM1 inhibitors

Chinese researchers present new glucose-lowering agents

Jiangsu Chia Tai Tianqing Pharmaceutical describes HBV antivirals

Discovery of novel IDO1 inhibitors for the treatment of cancer

RAPT Therapeutics patents USP7 inhibitors

Versameb's VMB-100 shows promise for stress urinary incontinence in animal model

Defence Therapeutics' AccuVAC-PT001 COVID-19 vaccine completes toxicology studies in rabbits

SLC6A14 polymorphism tied to cystic fibrosis severity

Burning Rock to support testing of Impact's ATR inhibitor IMP-9064

Computational prodding of evolutionary history gives clues to gene variants

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...